catumaxomab

A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2018
05101520062018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Cytoreductive surgery and chemotherapy continue to be the mainstay of ovarian cancer treatment. However, as mortality from… (More)
  • table 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as… (More)
Is this relevant?
2012
2012
Patients with malignant ascites secondary to primary carcinomas benefit from intraperitoneal therapy with the trifunctional… (More)
  • table 1
  • table 2
  • figure 2
  • figure 3
  • table 3
Is this relevant?
2012
2012
The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2011
2011
THE TRIFUNCTIONAL ANTIBODY (TRAB) CATUMAXOMAB IS CHARACTERIZED BY A UNIQUE ABILITY TO BIND THREE DIFFERENT CELL TYPES: tumor… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2011
2011
OBJECTIVE The aim of this study was to select the best catumaxomab regimen for further investigation in ovarian cancer based on… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2010
2010
The Triomab family of trifunctional, bispecific antibodies that maintain an IgG-like shape are novel tumor targeting agents… (More)
Is this relevant?
2010
2010
AIMS Catumaxomab is the first EMEA approved trifunctional anti-EpCAMxanti-CD3 antibody for the treatment of cancer patients with… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Malignant ascites in ovarian carcinoma patients is associated with poor prognosis and reduced quality of life. The… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?